AI-powered consulting at the intersection of multi-omics, drug discovery, and precision medicine — built for biotech and pharma leaders who need more than algorithms.
Omniomics.ai partners with life science organisations to deploy production-ready AI solutions across the full drug development and diagnostics pipeline — from target identification to clinical translation.
What we do
Accelerate your pipeline with knowledge-graph–powered target identification, compound prioritisation, and mechanism-of-action analysis. We integrate multi-omics datasets — genomics, transcriptomics, proteomics, metabolomics — to surface therapeutic hypotheses that traditional approaches miss.
Biotech and pharma teams at preclinical or early clinical stage seeking to compress timelines and de-risk candidate selection.
Raw biological data is only as valuable as the insight extracted from it. We design and deploy bespoke AI pipelines that harmonise heterogeneous omics data sources, resolve batch effects, and deliver interpretable, publication-quality outputs — ready for both regulatory review and commercial application.
Research teams, CROs, and diagnostics companies working with large-scale biological datasets.
From patient stratification to companion diagnostics, we help you define, validate, and commercialise biomarker signatures with clinical utility. Our AI frameworks are built for real-world clinical data environments, with a track record of translating findings from discovery through to validated assay development.
Oncology, immunology, and rare disease programmes seeking to embed precision medicine into their development strategy.
We design and validate AI diagnostic models — from algorithm conception and feature engineering through to clinical validation, regulatory alignment, and IP protection. Our team brings hands-on experience developing commercial-grade diagnostic platforms for global healthcare markets.
In vitro diagnostics companies, hospital networks, and digital health ventures seeking diagnostic AI with defensible evidence packages.
Not every challenge requires a full engagement. Our advisory service gives leadership teams access to senior AI expertise for technology evaluations, partnership structuring, grant strategy, investment readiness, and innovation roadmapping.
C-suite, boards, and R&D leadership across biotech, pharma, diagnostics, and health-tech.
Our approach
Omniomics.ai was founded on a straightforward conviction: that the most powerful AI in life sciences is only valuable if it can be deployed, validated, and trusted by the people who need it most.
We work at the frontier of artificial intelligence and biomedical science — but we remain stubbornly focused on outcomes. Every engagement begins with understanding your strategic objective, your data landscape, and your regulatory context. We then design and deliver AI solutions that are scientifically rigorous, computationally scalable, and built for real-world use.
Our consulting model draws on a deep network of specialised expertise spanning machine learning, systems biology, clinical informatics, and pharmaceutical R&D. We combine the intellectual depth of world-leading academic research with the pace, pragmatism, and accountability that industry demands.
Data → Intelligence → Outcome
Founder
Professor Fatemeh Vafaee — Founder & Principal Consultant
Omniomics.ai was founded by Professor Fatemeh Vafaee, one of the most recognised figures in applied AI for the life sciences. With a PhD in Artificial Intelligence from the University of Illinois at Chicago and more than 15 years translating advanced machine learning into deployable biomedical solutions, Professor Vafaee brings a rare combination of frontier research capability and end-to-end industry delivery.
Professor Vafaee leads the development of scalable AI platforms spanning the complete innovation pipeline — from algorithm design and multi-omics data integration through to clinical validation, commercial diagnostics, and protected intellectual property. Her work sits at the intersection of drug discovery, precision medicine, and AI diagnostics, with a proven ability to take research from hypothesis to market-ready technology.
As Co-founder of OmniTx.AI — a UNSW spin-out building knowledge-graph–powered AI systems for therapeutic development — Professor Vafaee has demonstrated that the highest-quality research can be translated into commercially significant, proprietary platforms. Her AI-identified drug targets in oncology are currently under evaluation in partnership with the Peter MacCallum Cancer Centre, one of the world's leading cancer research institutions.
Her track record includes over $19 million in secured funding from Australia's most competitive grant bodies — ARC, NHMRC, MRFF, and CRCP — as well as direct industry partnerships with listed and unlisted pharmaceutical and biotech companies.
For clients, engaging Omniomics.ai means direct access to this expertise — applied to your specific challenges, your data, and your timelines.
in competitive & industry funding
peer-reviewed publications
industry collaborations
years at the frontier of AI in biomedicine
Partnerships
What our partners say
At Tolemy Bio, we have had the pleasure of collaborating with Prof Fatemeh Vafaee on a project focused on profiling T-cell heterogeneity for allogeneic cell therapies. Fatemeh brings a rare combination of deep domain expertise, strategic insight, and collaborative spirit. Her guidance has been invaluable not only in shaping the scientific direction of the project but also in mentoring her team to deliver exceptional work. She is a fantastic partner — responsive, thoughtful, and always supremely technically engaged. We look forward to continuing this collaboration for many years to come.
Dr Alex Ward
Co-Founder, Tolemy Bio
We have found a great many synergies between Fatemeh's cutting-edge AI research and our own work. It has been a pleasure building this partnership and we look forward to many impactful outcomes of this collaboration.
Dr Simon Junankar
Scientific Director, Differentia Bio
It is a privilege to commend Professor Fatemeh Vafaee for her exceptional leadership in our collaboration with the University of New South Wales. As Principal Investigator for an AI-driven drug discovery platform developed for Algorae Pharmaceuticals, Professor Vafaee has skilfully translated cutting-edge research into transformative medical innovation. Her technical expertise and strategic vision enabled the timely delivery of the platform's minimum viable product, achieving the required Technology Readiness Level. The initial AI-identified oncology drug targets are now being evaluated in the wet lab in partnership with the prestigious Peter MacCallum Cancer Centre.
David Hainsworth
Chairman, Algorae Pharmaceuticals Ltd (ASX: 1AI)
Why Omniomics.ai
Our work is grounded in the same rigour that produces top-tier publications — but everything we build is designed to move into production. No proof-of-concept theatre. No black-box recommendations. Only AI solutions that hold up to scientific scrutiny and commercial stress-testing.
From raw multi-omics data to validated clinical outputs, we cover the entire AI development lifecycle. We are as comfortable advising on data infrastructure and model architecture as we are on regulatory strategy and IP structuring.
We have spent over 15 years working directly alongside pharmaceutical, biotech, diagnostics, and clinical teams. We understand your constraints — regulatory timelines, budget cycles, investor expectations, board-level reporting — and we design our engagements accordingly.
Every engagement is led by a recognised expert in applied AI for biomedicine. No layers of account managers — just a focused team translating frontier methods into deployable systems for your programme.
Get in touch
Whether you are evaluating AI for your pipeline, seeking a strategic partner for a funded programme, or ready to move a promising idea into development — we would like to hear from you.
Engagements range from single-day advisory sessions to multi-year embedded partnerships. All conversations are confidential.
